RecruitingNot ApplicableNCT04646707

Effect of Erector Spinae (ESP) Block on Opioid Reduction and Enhanced Recovery After Posterior Cervical Spine Surgery


Sponsor

University Health Network, Toronto

Enrollment

52 participants

Start Date

Feb 17, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

Patients undergoing spine surgery frequently experience significant pain after surgery. This can limit patient activity and hinder rehabilitation. If inadequately treated, severe pain can result in emotional and psychological distress and ultimately impact long-term function, and increase the risk of developing pain that lasts longer than six months associated with depression, anxiety and disability. More specifically, Erector Spinae Plane (ESP) block is a recently described plane block designed to block the dorsal and ventral rami of the thoracic spinal nerves. It has shown to be an effective modality for postoperative pain management as a part of multimodal analgesia in spinal surgery.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria1

  • All adult patients aged 18-80 years with ASA class I - III undergoing posterior cervical (C3-T2) decompression and instrumented fusion for cervical stenosis in prone position.

Exclusion Criteria7

  • In patients who are allergic to local anesthetics.
  • ASA IV patients
  • Lack of informed consent
  • Pregnant patient.
  • Fracture cervical spine
  • Extradural or intradural cervical tumors
  • Surgery of C1 and C2 spine

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGErector Spinae (ESP) Block with Lidocaine/Bupivacaine

Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)

DRUGErector Spinae (ESP) Block with placebo

Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline


Locations(1)

Toronto Western Hospital?UHN

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04646707


Related Trials